NewLimit

NewLimit, the company Coinbase's Brian Armstrong co-founded in 2021, raised $435 million at roughly a $3.1 billion valuation and says it will ask regulators to start human trials of its first drug in 2027 — years sooner than its own founders had planned for. The trigger was a lab result: a prototype made old human liver cells, in a dish, behave young again, and cut the damage markers livers leak in mouse injury models. That was enough to compress a research phase the team had expected to run more than a decade.

Two thousand transcription factors combine into roughly ten quadrillion possible treatments — far more than the stars in the Milky Way.

The drug is partial reprogramming — the idea that a brief, controlled dose of the molecular switches that wind a cell back toward its embryonic state can shed the marks of age without erasing what the cell is. NewLimit's version is mRNA wrapped in a fat bubble, the same delivery as a COVID vaccine, carrying fewer than ten gene-control proteins to the liver. Finding that handful is the hard part: the human genome has about 2,000 such proteins, which combine into roughly ten quadrillion possible cocktails, so the company built an AI screen that tags thousands of cells with different combinations at once and reads off which ones worked.

One thing the announcement underplays. NewLimit is not first to put reprogramming into a person — Life Biosciences already injected the factors into a glaucoma patient's eye in March 2026. What NewLimit would be first at is reprogramming an internal organ rather than a sealed-off eye, and a 2027 filing is an intent, not a dosed patient. 'Reversed cell age' here means a younger reading in a dish, not a rejuvenated organ in a body, and the field's central fear — that a cell told to grow young forgets to stop growing — has no human safety data behind it yet.

The signal isn't a cure; it's capital. With Eli Lilly's venture arm now on the cap table alongside the longevity-native funds, a major drugmaker is betting that resetting a cell's age is a buildable drug class — not a science-fiction goal but a pipeline.